US OptionsDetailed Quotes
CARA250117P5000
- 0.00
- 0.000.00%
15min DelayClose Dec 24 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover516.36%IV-979.91%PremiumJan 17, 2025Expiry Date4.54Intrinsic Value100Multiplier22DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8970Delta0.3574Gamma0.10Leverage Ratio-0.0020Theta-0.0013Rho-0.09Eff Leverage0.0002Vega
Cara Therapeutics Stock Discussion
Sign in to post a comment
$Cara Therapeutics (CARA.US)$ is there still hope? holding at .27. 🤞
8
NOTE!
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
7. I DO NOT give buy or sell advice
8. COH (cash on hand); AH (after hours): RTH (regular trading hours)
$Currenc Group (CURR.US)$ Despac Sk...
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
7. I DO NOT give buy or sell advice
8. COH (cash on hand); AH (after hours): RTH (regular trading hours)
$Currenc Group (CURR.US)$ Despac Sk...
64
39
13
$Cara Therapeutics (CARA.US)$
CSL Limited Reports 13.5% Stake in Cara Therapeutics Inc as of Oct 23 - SEC Filing
CSL Limited Reports 13.5% Stake in Cara Therapeutics Inc as of Oct 23 - SEC Filing
1
$Cara Therapeutics (CARA.US)$
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
Cara Therapeutics announced disappointing results from Part A of their KOURAGE-1 study, evaluating oral difelikefalin for notalgia paresthetica (NP). The drug did not show meaningful clinical benefit over placebo at any dose, leading the company to discontinue the clinical program in NP. The Phase 2/3 trial involved 214 patients, and despite the...
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
Cara Therapeutics announced disappointing results from Part A of their KOURAGE-1 study, evaluating oral difelikefalin for notalgia paresthetica (NP). The drug did not show meaningful clinical benefit over placebo at any dose, leading the company to discontinue the clinical program in NP. The Phase 2/3 trial involved 214 patients, and despite the...
3
$Cara Therapeutics (CARA.US)$
CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes30/04/2024 09:00AM ET
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic a...
CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes30/04/2024 09:00AM ET
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic a...
Cara Therapeutics' low P/S ratio reflects its declining revenues and bleak future growth projection. Per investors, the company's future may not yield a significant revenue improvement.
1
No comment yet
NercZ24 : yaaaayyyyy
你妈妈 : How are things going at the moment?
NercZ24 : im getting better at securing my profits and still hold shares
NercZ24 NercZ24 :